EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer

Zhuolong Xiong, Zenglei Han, Weiyi Pan, Xiao Zhu iD, Caixin Liu

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0286122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Zhuolong Xiong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, RNA, Long Noncoding, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromatin regulators drive cancer epigenetic changes, and lncRNA can play an important role in epigenetic changes as chromatin regulators. We used univariate Cox, LASSO, and multivariate Cox regression analysis to select epigenetic-associated lncRNA signatures. Twenty-five epigenetic-associated lncRNA signatures (CELncSig) were identified to establish the immune prognostic model. According to Kaplan-Meier analysis, the overall survival of the high-risk group was significantly lower than the low-risk group. Receiver operating characteristic (ROC) curves, C-index, survival curve, nomogram, and principal component analysis (PCA) were performed to validate the risk model. In GO/KEGG analysis, differentially expressed lncRNAs were correlated with the PI3K−Akt pathway, suggesting that they were highly associated with the metastasis of LUAD. Interestingly, in the immune escape analysis, the TIDE score was lower, and the possibility of immune dysfunction is also slighter in the high-risk group, which means they still have the potential to receive immunotherapy. And CELncsig is highly correlated with immune pathways T_cell_co-inhibition and Check-point. Also, the IMvigor210 cohort analysis indicated that our risk-scoring model has significant potential clinical application value in lung cancer immunotherapy. And we also screened out ten potential chemotherapy agents using the ‘pRRophetic’ package.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRNA, Long NoncodingLung NeoplasmsHumansChromatinPhosphatidylinositol 3-KinasesPrognosisEpigenesis, GeneticImmunotherapyTumor Microenvironment

Substanzen

ChromatinRNA, Long NoncodingPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China.
  • Computational Systems Biology Lab (CSBL), Institute of Bioinformatics, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.
  • Department of Pathology, Qingdao Municipal Hospital, Qingdao, China.
  • Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou Medical College, Hangzhou, China.

ORCID-Profile: Xiao Zhu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xiong, Z., Han, Z., Pan, W., Zhu, X., & Liu, C. (2023). Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0286122

Vancouver

Xiong Z, Han Z, Pan W, Zhu X, Liu C. Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer. PLOS ONE. 2023. doi:10.1371/journal.pone.0286122

BibTeX
@article{Xiong2023,
  author = {Xiong, Zhuolong and Han, Zenglei and Pan, Weiyi and Zhu, Xiao and Liu, Caixin},
  title = {Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0286122}
}
Kostenlos starten →